{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:19:06Z","timestamp":1791674346678,"version":"4.3.4"},"reference-count":95,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000568","name":"British Society for Rheumatology","doi-asserted-by":"publisher","award":["18,19"],"award-info":[{"award-number":["18,19"]}],"id":[{"id":"10.13039\/501100000568","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000568","name":"British Society for Rheumatology","doi-asserted-by":"publisher","award":["16,17"],"award-info":[{"award-number":["16,17"]}],"id":[{"id":"10.13039\/501100000568","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.berh.2025.102084","type":"journal-article","created":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T23:01:00Z","timestamp":1751842860000},"page":"102084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Novel therapies in Sj\u00f6gren\u2019s disease: A systematic review of the literature"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6787-4456","authenticated-orcid":false,"given":"Cristina","family":"Pelkas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle B.","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien B.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Rischmueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.berh.2025.102084_bib1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41584-023-01057-6","article-title":"Epidemiology of sj\u00f6gren syndrome","volume":"20","author":"Beydon","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102084_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","article-title":"Sj\u00f6gren's syndrome: a systemic autoimmune disease","volume":"22","author":"Negrini","year":"2022","journal-title":"Clin Exp Med"},{"issue":"6","key":"10.1016\/j.berh.2025.102084_bib3","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/annrheumdis-2016-209952","article-title":"Influence of geolocation and ethnicity on the phenotypic expression of primary Sj\u00f6gren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sj\u00f6gren Project Consortium","volume":"76","author":"Brito-Zer\u00f3n","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2025.102084_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152354","article-title":"Autoimmune rheumatic disease in Australian aboriginal and Torres Strait Islander peoples: what do we know?","volume":"65","author":"Eades","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2025.102084_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/ket349","article-title":"Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry)","volume":"53","author":"Ramos-Casals","year":"2014","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2025.102084_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct Targeted Ther"},{"issue":"8","key":"10.1016\/j.berh.2025.102084_bib7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41584-024-01135-3","article-title":"Update on the pathophysiology and treatment of primary Sj\u00f6gren syndrome","volume":"20","author":"Baldini","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2025.102084_bib8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0961203316678675","article-title":"Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study","volume":"26","author":"Burge","year":"2017","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.berh.2025.102084_bib9","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1093\/rheumatology\/kez052","article-title":"Lymphomas complicating primary Sj\u00f6gren's syndrome: from autoimmunity to lymphoma","volume":"60","author":"Nocturne","year":"2021","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.berh.2025.102084_bib10","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1093\/rheumatology\/keab364","article-title":"Mortality in patients with primary Sj\u00f6gren's syndrome: a systematic review and meta-analysis","volume":"60","author":"Huang","year":"2021","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.berh.2025.102084_bib11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2025.102084_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102062","article-title":"Mortality risk factors in primary Sj\u00f6gren syndrome: a real-world, retrospective, cohort study","volume":"61","author":"Brito-Zer\u00f3n","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"3","key":"10.1016\/j.berh.2025.102084_bib13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sj\u00f6gren's syndrome","volume":"46","author":"Ioannidis","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2025.102084_bib14","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s10067-022-06119-w","article-title":"A comprehensive overview of living with Sj\u00f6gren's: results of a National Sj\u00f6gren's Foundation survey","volume":"41","author":"McCoy","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102084_bib15","first-page":"98","article-title":"Sjogren's syndrome: managed care data from a large United States population highlight real-world health care burden and lack of treatment options","volume":"35","author":"Birt","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102084_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2025.102084_bib17","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/rheumatology\/keaa870","article-title":"The management of Sjogren's syndrome: British Society for Rheumatology guideline scope","volume":"60","author":"Price","year":"2021","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.berh.2025.102084_bib18","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s10067-017-3822-3","article-title":"Primary Sjogren's syndrome: extraglandular manifestations and hydroxychloroquine therapy","volume":"36","author":"Demarchi","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2025.102084_bib19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.55563\/clinexprheumatol\/volsh1","article-title":"Hypergammaglobulinaemia predicts glandular and extra-glandular damage in primary Sj\u00f6gren's syndrome: results from the KISS cohort study","volume":"39","author":"Koh","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2025.102084_bib20","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/ard.2006.060905","article-title":"Safety and efficacy of leflunomide in primary Sj\u00f6gren's syndrome: a phase II pilot study","volume":"66","author":"van Woerkom","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2025.102084_bib21","first-page":"555","article-title":"Methotrexate in primary Sj\u00f6gren's syndrome","volume":"14","author":"Skopouli","year":"1996","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2025.102084_bib22","first-page":"896","article-title":"A double blind placebo controlled trial of azathioprine in the treatment of primary Sj\u00f6gren's syndrome","volume":"25","author":"Price","year":"1998","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2025.102084_bib23","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar2322","article-title":"Mycophenolate sodium treatment in patients with primary Sj\u00f6gren syndrome: a pilot trial","volume":"9","author":"Willeke","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2025.102084_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2025.102084_bib25","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"issue":"9","key":"10.1016\/j.berh.2025.102084_bib26","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nrrheum.2013.110","article-title":"Advances in understanding the pathogenesis of primary Sj\u00f6gren's syndrome","volume":"9","author":"Nocturne","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2025.102084_bib27","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/rheumatology\/kez142","article-title":"Treatment of Sjogren's syndrome: current therapy and future directions","volume":"60","author":"Fox","year":"2021","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.berh.2025.102084_bib28","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.berh.2025.102084_bib29","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary sjogren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2025.102084_bib30","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/art.39088","article-title":"Brief report: ultrasonographic assessment of salivary gland response to rituximab in primary sjogren's syndrome","volume":"67","author":"Jousse-Joulin","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2025.102084_bib31","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/annrheumdis-2017-212268","article-title":"Effect of rituximab on a salivary gland ultrasound score in primary Sjogren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy","volume":"77","author":"Fisher","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"10.1016\/j.berh.2025.102084_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sjogren's syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI insight"},{"issue":"10320","key":"10.1016\/j.berh.2025.102084_bib33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.berh.2025.102084_bib34","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sjogren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"Dorner","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2025.102084_bib35","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/rheumatology\/keaa410","article-title":"A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjogren's syndrome","volume":"60","author":"Juarez","year":"2021","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.berh.2025.102084_bib36","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2025.102084_bib38","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.41489","article-title":"Improvement of severe fatigue following nuclease therapy in patients with primary sjogren's syndrome: a randomized clinical trial","volume":"73","author":"Posada","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2025.102084_bib39","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","article-title":"Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sj\u00f6gren\u2019s syndrome: a randomized, phase 2, double-blind, placebo-controlled study","volume":"61","author":"Price","year":"2022","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.berh.2025.102084_bib40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2020-218467","article-title":"Interleukin 6 receptor inhibition in primary Sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial","volume":"80","author":"Felten","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2025.102084_bib41","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","article-title":"CD40 ligand antagonist dazodalibep in Sj\u00f6gren\u2019s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial","volume":"30","author":"St Clair","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.berh.2025.102084_bib42","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2025.102084_bib43","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.40513","article-title":"Clinical efficacy and safety of baminercept, a lymphotoxin beta receptor fusion protein, in primary sjogren's syndrome: results from a phase II randomized, double-blind, placebo-controlled trial","volume":"70","author":"St Clair","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2025.102084_bib44","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet. Rheumatol."},{"issue":"11","key":"10.1016\/j.berh.2025.102084_bib45","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1093\/rheumatology\/kead092","article-title":"A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sj\u00f6gren's syndrome","volume":"62","author":"Bentley","year":"2023","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.berh.2025.102084_bib46","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000551","article-title":"Topical fluorometholone treatment for ocular dryness in patients with Sjogren syndrome: a randomized clinical trial in China","volume":"94","author":"Lin","year":"2015","journal-title":"Medicine (Baltim)"},{"issue":"1","key":"10.1016\/j.berh.2025.102084_bib47","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1120672121992680","article-title":"Evaluation of the effect of topical tacrolimus 0.03 % versus cyclosporine 0.05 % in the treatment of dry eye secondary to Sjogren syndrome","volume":"32","author":"Moawad","year":"2022","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"10.1016\/j.berh.2025.102084_bib48","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clae.2015.04.004","article-title":"Treatment of Sjogren's syndrome dry eye using 0.03 % tacrolimus eye drop: prospective double-blind randomized study","volume":"38","author":"Moscovici","year":"2015","journal-title":"Contact Lens Anterior Eye"},{"issue":"2","key":"10.1016\/j.berh.2025.102084_bib49","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/odi.13251","article-title":"Patient-related outcomes in Sjogren syndrome treated with stimulants of salivary secretion: randomized clinical trial","volume":"26","author":"da Mata","year":"2020","journal-title":"Oral Dis"},{"issue":"2","key":"10.1016\/j.berh.2025.102084_bib50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/03009742.2020.1809701","article-title":"Efficacy and safety of iguratimod on patients with primary Sjogren's syndrome: a randomized, placebo-controlled clinical trial","volume":"50","author":"Shao","year":"2021","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2025.102084_bib51","first-page":"1077","article-title":"Rituximab therapy in primary Sjogren's syndrome with interstitial lung disease: a retrospective cohort study","volume":"34","author":"Chen","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2025.102084_bib52","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3899\/jrheum.160459","article-title":"Detailed analysis of the articular domain in patients with primary sjogren syndrome","volume":"44","author":"Moerman","year":"2017","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102084_bib53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3899\/jrheum.160313","article-title":"B cell depletion therapy normalizes circulating follicular Th cells in primary sjogren syndrome","volume":"44","author":"Verstappen","year":"2017","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2025.102084_bib54","first-page":"2249","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sjogren's syndrome: the BELISS open-label phase II study","volume":"54","author":"De Vita","year":"2015","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.berh.2025.102084_bib55","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2025.102084_bib56","first-page":"311","article-title":"Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjogren's syndrome: follow-up after the end of the phase II open-label BELISS study","volume":"34","author":"Quartuccio","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2025.102084_bib57","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/ceo.12898","article-title":"Increased corneal sub-basal nerve density in patients with Sjogren syndrome treated with topical cyclosporine A","volume":"45","author":"Levy","year":"2017","journal-title":"Clin Experiment Ophthalmol"},{"issue":"1","key":"10.1016\/j.berh.2025.102084_bib58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.autrev.2018.06.015","article-title":"Arthritis in primary Sjogren's syndrome: characteristics, outcome and treatment from French multicenter retrospective study","volume":"18","author":"Mirouse","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.berh.2025.102084_bib59","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.medcli.2024.06.012","article-title":"Efficacy of disease-modifying antirheumatic drugs in primary Sjogren's syndrome-related interstitial lung disease","volume":"163","author":"Erbasan","year":"2024","journal-title":"Med Clin"},{"issue":"1","key":"10.1016\/j.berh.2025.102084_bib60","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10067-019-04724-w","article-title":"Effectiveness and safety of abatacept for the treatment of patients with primary Sjogren's syndrome","volume":"39","author":"Machado","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2025.102084_bib61","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1007\/s10067-016-3360-4","article-title":"A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjogren's syndrome","volume":"35","author":"Kedor","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2025.102084_bib62","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","article-title":"Symptom-based stratification of patients with primary Sj\u00f6gren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials","volume":"1","author":"Tarn","year":"2019","journal-title":"Lancet. Rheumatol."},{"issue":"9","key":"10.1016\/j.berh.2025.102084_bib63","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00296-021-04927-y","article-title":"Revisiting the JOQUER trial: stratification of primary Sjogren's syndrome and the clinical and interferon response to hydroxychloroquine","volume":"41","author":"Collins","year":"2021","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.berh.2025.102084_bib64","first-page":"182","article-title":"Do antimalarials protect against damage accrual in primary Sjogren's syndrome? Results from a Latin-American retrospective cohort","volume":"36","author":"Hernandez-Molina","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2025.102084_bib65","first-page":"136","article-title":"Treatment of primary sjogren's syndrome-related interstitial lung disease: a retrospective cohort study","volume":"37","author":"Amlani","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"7","key":"10.1016\/j.berh.2025.102084_bib66","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/jop.2015.0081","article-title":"The efficacy of diquafosol ophthalmic solution in non-sjogren and sjogren syndrome dry eye patients unresponsive to artificial tear","volume":"32","author":"Jeon","year":"2016","journal-title":"J Ocul Pharmacol Therapeut"},{"issue":"5","key":"10.1016\/j.berh.2025.102084_bib67","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/jop.2016.0166","article-title":"The effect of immunologically safe plasma rich in growth factor eye drops in patients with sjogren syndrome","volume":"33","author":"Sanchez-Avila","year":"2017","journal-title":"J Ocul Pharmacol Therapeut"},{"issue":"8","key":"10.1016\/j.berh.2025.102084_bib68","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1089\/jop.2020.0146","article-title":"Efficacy of switching from cyclosporine A 0.05 % anionic emulsion to cyclosporine A 0.1 % cationic emulsion in patients with dry eye associated with sjogren's syndrome","volume":"37","author":"Kim","year":"2021","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.berh.2025.102084_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2024.100238","article-title":"Treatment of non-systemic Sjogren's syndrome: potential prevention of systematization with immunosuppressant agent\/biotherapy","volume":"8","author":"Belbezier","year":"2024","journal-title":"J Transl Autoimmun"},{"issue":"2","key":"10.1016\/j.berh.2025.102084_bib70","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2025.102084_bib71","article-title":"Clinical efficacy and patient-reported outcomes in anti-ro\/sj\u00f6gren\u2019s syndrome\u2013related antigen a antibody\u2013positive patients with active SLE treated with deucravacitinib in the phase 2 PAISLEY trial [abstract]","volume":"76","author":"Fisher","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2025.102084_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107904","article-title":"The PI3Kdelta inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sjogren's syndrome","volume":"98","author":"Scuron","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.berh.2025.102084_bib74","article-title":"Impact of the COVID-19 pandemic on non-COVID-19 clinical trials","volume":"9","author":"Audisio","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"issue":"3","key":"10.1016\/j.berh.2025.102084_bib75","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sj\u00f6gren's syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2025.102084_bib76","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2025.102084_bib77","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sj\u00f6gren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren's Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2025.102084_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren's syndrome--a double blind, randomised clinical trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.berh.2025.102084_bib79","first-page":"97","article-title":"Systemic manifestations of primary Sj\u00f6gren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients","volume":"37","author":"Retamozo","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2025.102084_bib80","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of Relevant Endpoints for Sj\u00f6gren's Syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet. Rheumatol."},{"issue":"7","key":"10.1016\/j.berh.2025.102084_bib81","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","article-title":"Development and preliminary validation of the Sj\u00f6gren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren's syndrome","volume":"81","author":"Seror","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2025.102084_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152378","article-title":"The Sj\u00f6gren's Working Group: the 2023 OMERACT meeting and provisional domain generation","volume":"65","author":"Gordon","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2025.102084_bib83","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13293-015-0037-7","article-title":"Sex differences in Sj\u00f6gren's syndrome: a comprehensive review of immune mechanisms","volume":"6","author":"Brandt","year":"2015","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.berh.2025.102084_bib84","unstructured":"US Department of Health and Human Services Food and Drug Administration. Patient Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient\u2019s Voice in Medical Product Development and Regulatory Decision Making [updated 21\/3\/2025. Available from: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical.."},{"key":"10.1016\/j.berh.2025.102084_bib85","article-title":"Efficacy and safety of nipocalimab, an anti-FcRn monoclonal antibody, in primary Sjogren's disease: results from a phase 2, multicenter, randomized, placebo-controlled, double-blind study (DAHLIAS)","volume":"76","author":"Gottenberg","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"10416","key":"10.1016\/j.berh.2025.102084_bib86","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.berh.2025.102084_bib87","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.berh.2025.102084_bib88","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 car T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"10379","key":"10.1016\/j.berh.2025.102084_bib89","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2025.102084_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1298815","article-title":"Concurrent remission of lymphoma and Sj\u00f6gren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report","volume":"14","author":"Sheng","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2025.102084_bib91","series-title":"Universal CAR-T cells (BRL-301) in relapse or refractory autoimmune diseases","year":"2024"},{"issue":"9","key":"10.1016\/j.berh.2025.102084_bib92","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.berh.2025.102084_bib93","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41435-023-00221-y","article-title":"IL-2 immunotherapy for targeting regulatory T cells in autoimmunity","volume":"24","author":"Lykhopiy","year":"2023","journal-title":"Gene Immun"},{"key":"10.1016\/j.berh.2025.102084_bib94","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13075-015-0750-y","article-title":"Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjogren's syndrome: results of the BELISS study","volume":"17","author":"Seror","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2025.102084_bib95","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European league against rheumatism classification criteria for primary Sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2025.102084_bib96","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2025.102084_bib97","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169422500052X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169422500052X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T17:13:03Z","timestamp":1765386783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169422500052X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S152169422500052X"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2025.102084","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapies in Sj\u00f6gren\u2019s disease: A systematic review of the literature","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2025.102084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102084"}}